Safety Clinical Trial - Prospective G7 Dual Mobility Total Hip PMCF

Status Active, not recruiting

Clinical Trial Summary

This is a prospective multi-center clinical evaluation following recipients of the G7 Dual Mobility hip device. The primary objective is to characterize survivorship of the G7 hip at five years post-index procedure. Secondary objectives include documentation of clinical outcomes, safety and radiographic data.

Clinical Trial Description

This multi-center prospective follow-up study will evaluate clinical outcomes, functional outcomes, radiological outcomes and further characterize the safety profile of the G7 Dual Mobility Hip Arthroplasty System. This will be accomplished by assessing these domains using the Harris Hip Score, UCLA Activity Score, and EQ-5D-3L, obtaining and assessing radiographs and the tracking of device or procedure related adverse events. Subjects will undergo unilateral primary or revision total hip arthroplasty and will then be followed for 10 years with intervals at 6 weeks, 1-, 2-, 3- 5- and 10 years. For the 10 year visit, subjects will not be required to present in their doctor's office, but will fill out a survey. Subsequent to 10 year data collection, the subject's participation in the study will be compete. ;

Study Design

Related Conditions & MeSH terms

Clinical Trial Details

NCT number	NCT03308929
Study type	Observational
Source	Zimmer Biomet
Contact
Status	Active, not recruiting
Phase
Start date	February 28, 2017
Completion date	February 28, 2029

View Details

See also
Status	Clinical Trial	Phase
Recruiting	`NCT05073744` - Nalbuphine Versus Morphine for Perioperative Tumor Ablation	Phase 4
Completed	`NCT03969641` - Safety of RIV4 Versus IIV4 in Pregnant Women	Phase 4
Completed	`NCT05592951` - Safety and Tolerability of a Novel Amino-acid Based Hydration Drink in Healthy Volunteers	N/A
Completed	`NCT04693429` - Clinical Study for the Evaluation of Safety and Tolerability of PRO-172 Ophthalmic Solution+	Phase 1
Completed	`NCT01636024` - To Assess the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Ascending Doses of Inhaled AZD7594	Phase 1
Completed	`NCT01415102` - A First In Human Study In Healthy People To Evaluate Safety, Toleration And Time Course Of Plasma Concentration Of Single Inhaled Doses Of PF-05212372.	Phase 1
Completed	`NCT01243502` - A Study to Assess the Pharmacokinetics, Safety and Tolerability of CT327 in Healthy Male Volunteers	Phase 1
Completed	`NCT06072170` - Single Ascending Doses of Kratom in Healthy Nondependent Adults With Opioid Experience	Phase 1
Completed	`NCT05076253` - Efficacy of Ivermectin in COVID-19	Phase 1/Phase 2
Recruiting	`NCT06060379` - Giochiamo 626 - Gaming for Health and Safety in Workplaces	N/A
Recruiting	`NCT05298800` - Combined Immunization of COVID-19 Inactivated Vaccine With QIV and PPV23	Phase 4
Completed	`NCT05188638` - Safety of Ascending Single and Multiple Doses of Nebulised SoftOx Inhalation Solution in Healthy Subjects	Phase 1
Completed	`NCT05145621` - Oral Bio-equivalence Study	Phase 1
Recruiting	`NCT05580159` - New Generation mRNA Booster Vaccine Against Emerging VOCs	Phase 3
Not yet recruiting	`NCT04596956` - Safety and Efficacy of Sodium Bicarbonate Ringer Injection	Phase 4
Completed	`NCT03033329` - Single Dose Escalation and Multiple Dose Escalation Trial of an Intravenous Formulation of MRX-4	Phase 1
Terminated	`NCT01929811` - NeoMET Study in Neoadjuvant Treatment of Breast Cancer	Phase 2
Completed	`NCT01193335` - Study Evaluating a 13-valent Pneumococcal Conjugate Vaccine in Preterm Compared to Term Infants.	Phase 4
Completed	`NCT03300466` - A Study to Evaluate the Performance and Safety of GP0045 for Correction of Moderate to Severe Nasolabial Folds	N/A
Active, not recruiting	`NCT05686161` - mRNA Booster Vaccine(SW-BIC-213) Compared With Pfizer andSinopharm Against Emerging VOCs	Phase 3